tiprankstipranks
AdaptHealth (AHCO)
NASDAQ:AHCO
US Market
Want to see AHCO full AI Analyst Report?

AdaptHealth (AHCO) Earnings Dates, Call Summary & Reports

334 Followers

Earnings Data

Report Date
Aug 11, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.16
Last Year’s EPS
0.22
Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 05, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlights a major strategic win — completion of a large capitated transition, robust organic revenue growth (9.1% y/y), strong segment performance (notably Sleep and Respiratory), important technology milestones, and a refinancing that improves financial flexibility. Near-term challenges include elevated transition-related labor costs ($12M), a Q1 adjusted EBITDA miss (~$7M), negative free cash flow in the quarter due to elevated CapEx ($121.2M), and a temporary increase in leverage to ~3.0x. Management expects labor costs and CapEx to normalize by mid-year, maintains full-year EBITDA and free cash flow guidance, and raised revenue guidance slightly. Overall, strategic progress and forward-looking actions appear to outweigh the near-term execution and cash impacts.
Company Guidance
AdaptHealth raised full‑year net revenue guidance by $10M to $3.45B–$3.52B while maintaining adjusted EBITDA guidance of $680M–$730M and free cash flow guidance of $175M–$225M; for Q2 management expects net revenue of $840M–$860M and an adjusted EBITDA margin of ~19% (implying just over $160M of EBITDA), with free cash flow modest/positive as CapEx steps up to support the new capitated contract. In Q1 the company reported revenue of $819.8M (+5.4% YoY, 9.1% organic), adjusted EBITDA of $121.2M (14.8% margin), cash flow from operations of $93.7M, free cash flow of –$27.5M and CapEx of $121.2M; capitated revenue was $74.9M (9.2% of consolidated revenue) and capitated membership rose ~7x to ~15M. Balance‑sheet and financing targets include unrestricted cash of ~$48M, net debt of ~$1.84B (3.0x net leverage vs. 2.75x in Q4), a $1.1B refinancing ( $325M TLA / $325M delayed draw / $450M revolver maturing Apr 2031) and a target net leverage of 2.5x; elevated Q1 labor costs of ~$12M ($8M variable, $4M wage/benefit) should normalize by end‑Q2 with full benefit by Q3, and management expects FCF to normalize with roughly $100M in each of Q3 and Q4.
Successful Large-Scale Capitated Transition
Completed the largest patient transition in HME history, establishing 35 de novo locations and becoming the exclusive HME provider for >10 million new members; capitated membership increased ~7x year-over-year to about 15 million and capitated net revenue comprised 9.2% of consolidated net revenue in Q1.
Revenue Growth and Organic Performance
First quarter net revenue of $819.8 million, up 5.4% versus prior year and ~ $22 million ahead of midpoint guidance; organic growth was 9.1% year-over-year (about 500 bps from the new capitated contract and ~400 bps from base business).
Strong Segment Results — Sleep and Respiratory
Sleep Health net revenue $358.5 million, up 13.3% year-over-year with PAP new starts at a record; Respiratory Health net revenue $178.1 million, up 7.6% year-over-year and oxygen new starts grew 12.8%.
Wellness at Home Organic Recovery After Dispositions
Reported Wellness at Home net revenue declined 10.3% to $141.0 million due to $35.8 million of disposed revenue from noncore assets; after adjusting for dispositions, Wellness at Home delivered 11% organic growth.
Technology and Digital Milestones
AI-enabled initiatives moved beyond pilot with conversational AI handling live calls (scheduling, contact center, resupply); scheduling is now ~25% touchless versus manual a year ago; patient portal MyApp surpassed 412,000 users, and order conversion times shortened materially.
Refinancing Strengthens Financial Flexibility
Completed $1.1 billion refinancing in April (Term Loan A $325M, delayed draw $325M, $450M revolver) extending maturities to April 2031, lowering weighted average cost of debt and reflecting recent S&P and Moody's upgrades.
Raised Full-Year Revenue Guidance and Maintained Profitability Targets
Raised full-year net revenue projection by $10 million to $3.45B–$3.52B and maintained full-year adjusted EBITDA guidance of $680M–$730M and free cash flow guidance of $175M–$225M.
Operational Cash Flow and Outlook for Cash Generation
Q1 cash flow from operations $93.7 million (essentially flat year-over-year); company expects CapEx normalization and improving free cash flow in back half of the year, forecasting Q3 and Q4 cash flow strength (~$100 million each).

AdaptHealth (AHCO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

AHCO Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 11, 2026
2026 (Q2)
0.16 / -
0.218
May 05, 2026
2026 (Q1)
0.01 / -0.06
0.027-307.41% (-0.08)
Feb 24, 2026
2025 (Q4)
0.35 / 0.23
0.427-47.31% (-0.20)
Nov 04, 2025
2025 (Q3)
0.24 / 0.24
0.2245.80% (+0.01)
Aug 05, 2025
2025 (Q2)
0.16 / 0.22
0.2160.93% (<+0.01)
May 06, 2025
2025 (Q1)
0.05 / 0.03
0.093-70.97% (-0.07)
Feb 25, 2025
2024 (Q4)
0.28 / 0.43
0.556-23.20% (-0.13)
Nov 05, 2024
2024 (Q3)
0.19 / 0.22
0.415-46.02% (-0.19)
Aug 06, 2024
2024 (Q2)
0.19 / 0.22
0.228-5.26% (-0.01)
May 07, 2024
2024 (Q1)
0.05 / 0.09
0.05182.35% (+0.04)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

AHCO Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 05, 2026
$13.04$11.75-9.89%
Feb 24, 2026
$10.29$8.86-13.95%
Nov 04, 2025
$9.09$10.67+17.38%
Aug 05, 2025
$9.11$10.11+10.98%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AdaptHealth (AHCO) report earnings?
AdaptHealth (AHCO) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
    What is AdaptHealth (AHCO) earnings time?
    AdaptHealth (AHCO) earnings time is at Aug 11, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is AHCO EPS forecast?
          AHCO EPS forecast for the fiscal quarter 2026 (Q2) is 0.16.

            AdaptHealth (AHCO) Earnings News

            AdaptHealth Crashes after Q4 Earnings Miss
            Premium
            Market News
            AdaptHealth Crashes after Q4 Earnings Miss
            3y ago